The drug acts by inhibiting SARS-CoV-2 from replicating in the human system
News
NICE does not recommend tucatinib for advanced breast cancer
Tucatinib, a tyrosine kinase inhibitor, works by blocking a specific area of the HER2 gene in cancer cells
Roche launches Foundation Medicine-partnered genomic profiling kit
Product designed to allow laboratories to expand in-house oncology research
EC approves Keytruda regimen for triple-negative breast cancer
Approval covers patients with locally recurrent or metastatic TNBC
Rishi Sunak promises £6 billion package for health service
Package was announced during a speech at the annual Conservative Party Conference in Manchester, UK
Sajid Javid: NHS likely to have mandatory vaccinations
Javid also announced the government’s ‘five pillar’ plan for addressing COVID-19 during the challenging winter months
UK doctors: Renewed COVID response is urgent
The British Medical Association (BMA) has accused the Health Secretary of being “willfully negligent”.
US approval for J&J and Moderna COVID-19 boosters
EUA amendments ‘based on the available data and information’
Dupixent hits all endpoints in prurigo nodularis trial
Dupixent significantly reduced itch and skin lesions compared to placebo in the investigational trial setting
NICE recommends gene silencing therapy for porphyria patients on NHS
Givlaari uses ‘gene silencing’ RNA interference technology, to target the production of pathogenic compounds in people AHP
Antengene to collaborate with LegoChem Biosciences for antibody-drug conjugates
The two parties will jointly generate and evaluate ADC candidates
Psychoactive compound to advance research in treatment of depressive disorders
Lucid-PSYCH is a psychoactive compound potentially viable for the treatment of major depressive disorders
Biotage acquires DNA synthesis and purification company ATDBio
ATDBio adds important platform solutions to Biotage within DNA and RNA oligonucleotide synthesis and purification
Scancell gains new facilities at The Oxford Science Park
Scancell has taken new laboratory and office space in the Bellhouse Building at TOSP
Vertex’s type 1 diabetes therapy hits the mark in Phase I/II study
Results are ‘unprecedented’ according to company
